DFX Intelligence

Data Factory

VentureFirmmulti stage vcexempt_reporting_adviser

NGN Capital LLC

Venture Capital

Stamford, CT

This is the graph view. The full profile, with its team, deals and sources, is on Venture Capital.Open the full profile →

Search this name across graphsid dfx:vc:30e453fb-5336-4dd7-988a-29bd6e35ca35

Data as of Sep 17, 2026 (this record's last observation) from federal regulator filings, firm and issuer disclosures. Page built Sep 18, 2026, 11:00 PM UTC and rebuilt at most every 15 minutes.

Relationships: 16
Dated events: 19
On other graphs: 0
Observed: Sep 12, 2026 to Sep 17, 2026
47 observations

Across DFX

This entity has not been resolved onto another DFX graph by a shared identifier. A name match elsewhere would be a candidate, never an identity, and none is recorded.

Facts

fact = as filed or announced; derived = computed by DFX; estimate = a band, never a point

Funds: 9
Vintages: 2007 to 2020
Funds with fundraising evidence: 0derived
Investments: 0
Portfolio companies: 0
Investments, 12m: 0
Partner-attributed: 0
People: 6
Investment professionals: 6derived
Co-investors: 0derived
LP relationships: 0
Stated geography: new york,united states
Latest Form D: Mar 11, 2010
Latest ADV filing: Mar 19, 2026
Website: ngncapital.com

Funds

Fund	Vintage	Lifecycle	Form D sold	GAV
NGN Optiscan Fund II, LP	2020	Wound down	n/a	$1.8M
NGN Optiscan Fund III, LP	2020	Wound down	n/a	$999,981
NGN Optiscan Fund I, LP	2019	Wound down	n/a	$2.3M
NGN Biomed Opportunity Annex Fund (german Feeder) Gmbh & Co Kg	2014	Wound down	n/a	$126,485
NGN Biomed Opportunity Annex Fund LP	2014	Wound down	n/a	$184,501
NGN Biomed 2a	2007	Harvest	$173M	$99.2M
NGN Biomed 1b	n/a	Wound down	n/a	$43,504
NGN Biomed 2b	n/a	Unknown	n/a	$26.1M
NGN Biomed 1a	n/a	Wound down	n/a	$0

Relationships

Employs (6)

→ Kenneth S. AbramowitzPersonManaging General Partner
factThe subject's own site
→ John R. CostantinoPersonManaging General Partner
factThe subject's own site
→ Peter JohannPersonManager
Jan 1, 2006 to presentfactForm ADV, The subject's own site
→ Kenneth Samuel AbramowitzPersonManager
Apr 1, 2004 to presentfactForm ADV
→ John Richard CostantinoPersonManager
Jan 1, 2006 to presentfactForm ADV
→ Georg NebgenPersonManager
Apr 1, 2004 to Apr 25, 2014inferenceForm ADV

Manages (9)

→ NGN Biomed Opportunity Annex Fund LPFundVenture Capital Fund
Apr 25, 2014 to presentfactForm ADV
→ NGN Optiscan Fund I, LPFundVenture Capital Fund
Mar 18, 2019 to presentfactForm ADV
→ NGN Optiscan Fund III, LPFundVenture Capital Fund
Mar 30, 2020 to presentfactForm ADV
→ NGN Optiscan Fund II, LPFundVenture Capital Fund
Mar 30, 2020 to presentfactForm ADV
→ NGN Biomed 1aFundVenture Capital Fund
Mar 30, 2012 to presentfactForm ADV
→ NGN Biomed 2bFundVenture Capital Fund
Mar 30, 2012 to presentfactForm ADV
→ NGN Biomed 2aFundVenture Capital Fund
Mar 30, 2012 to presentfactForm ADV
→ NGN Biomed 1bFundVenture Capital Fund
Mar 30, 2012 to presentfactForm ADV
→ NGN Biomed Opportunity Annex Fund (german Feeder) Gmbh & Co KgFundVenture Capital Fund
Apr 25, 2014 to presentfactForm ADV

Dated events

17 bookkeeping events (roster, classification and holdings changes) folded below

Occurred
Apr 25, 2014
Person left
Georg Nebgen (Manager) no longer on Schedule A of NGN Capital LLC
Form ADVobserved 6 days ago
Occurred
Mar 30, 2012
Adviser's first ADV filing
NGN Capital LLC first filed Form ADV (ERA, venture capital fund adviser exemption)
Form ADVobserved 6 days ago

Show 17 bookkeeping events

First seen by DFX
Sep 15, 2026
date not stated
NGN Capital LLC: INSTITUTIONAL_VC -> MULTI_STAGE_VC (both early and growth/opportunity families, reported GAV $125M)
Occurred
Mar 15, 2024
NGN Biomed 1b no longer reported on Form ADV by NGN Capital LLC
Occurred
Mar 20, 2023
NGN Biomed 1a no longer reported on Form ADV by NGN Capital LLC
Occurred
Mar 24, 2022
NGN Biomed Opportunity Annex Fund LP no longer reported on Form ADV by NGN Capital LLC
Occurred
Mar 24, 2022
NGN Biomed Opportunity Annex Fund (german Feeder) Gmbh & Co Kg no longer reported on Form ADV by NGN Capital LLC
Occurred
Mar 18, 2021
NGN Optiscan Fund I, LP no longer reported on Form ADV by NGN Capital LLC
Occurred
Mar 18, 2021
NGN Optiscan Fund II, LP no longer reported on Form ADV by NGN Capital LLC
Occurred
Mar 18, 2021
NGN Optiscan Fund III, LP no longer reported on Form ADV by NGN Capital LLC
Occurred
Mar 30, 2020
NGN Optiscan Fund III, LP first reported on Form ADV by NGN Capital LLC (Venture Capital Fund), GAV $999,981
Occurred
Mar 30, 2020
NGN Optiscan Fund II, LP first reported on Form ADV by NGN Capital LLC (Venture Capital Fund), GAV $1,776,623
Occurred
Mar 18, 2019
NGN Optiscan Fund I, LP first reported on Form ADV by NGN Capital LLC (Venture Capital Fund), GAV $2,273,290
Occurred
Apr 25, 2014
NGN Biomed Opportunity Annex Fund (german Feeder) Gmbh & Co Kg first reported on Form ADV by NGN Capital LLC (Venture Capital Fund), GAV $14,100,000
Occurred
Apr 25, 2014
NGN Biomed Opportunity Annex Fund LP first reported on Form ADV by NGN Capital LLC (Venture Capital Fund), GAV $18,600,000
Occurred
Mar 30, 2012
NGN Biomed 1a first reported on Form ADV by NGN Capital LLC (Venture Capital Fund), GAV $49,700,000
Occurred
Mar 30, 2012
NGN Biomed 1b first reported on Form ADV by NGN Capital LLC (Venture Capital Fund), GAV $35,900,000
Occurred
Mar 30, 2012
NGN Biomed 2a first reported on Form ADV by NGN Capital LLC (Venture Capital Fund), GAV $142,200,000
Occurred
Mar 30, 2012
NGN Biomed 2b first reported on Form ADV by NGN Capital LLC (Venture Capital Fund), GAV $40,350,000

Who to call

the organisation, the role and the published line, with the filing or website that published it; revealed to signed-in accounts

The firm's published line

Revealable: 1 business phone (Form ADV), 1 website (Form ADV), 1 work email (firm website) · as of 2026-09-16

Also named here, with no published line of their own (reach them through the firm): Kenneth S. Abramowitz (Managing General Partner), John R. Costantino (Managing General Partner), Peter Johann (Manager), Kenneth Samuel Abramowitz (Manager), John Richard Costantino (Manager).

Who to call is the organisation, the person's role and the line they published themselves: a business phone, office address, website or profile link from Form ADV, Form 13F or their own website, with that source named on every value. The counts above are what a reveal returns; a personal email is rarely published, so most reveals are the firm's line. Never data bought from a provider, never anything personal. Reveals by plan